Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard Immunosuppressive Therapy Plus Umbilical Cord Blood Mononuclear Cells for Severe Aplastic Anemia
ChiCTR2600117810Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall response rate at 4, 8, and 12 weeks after IST and Complete response rate at 4, 8, and 12 weeks after IST. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2600117810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117810.